Analysis of clinical value of procalcitonin combined with D-dimer test in evaluating prognosis of patients with acute exacerbation of acute chronic obstructive pulmonary disease complicated by type Ⅱ respiratory failure
Objective This study aims to evaluate the roles of procalcitonin and D-dimer in the prognosis of patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) complicated by type Ⅱ respiratory failure. By measuring the levels of these biomarkers,we aimed to understand if they could serve as effective predictors of patients' prognosis. Methods The study included 94 patients with acute exacerbation of COPD complicated by type Ⅱ respiratory failure and 50 healthy controls. Standard drug therapy was administered according to current guidelines,and all patients were followed up. Based on the 28-day survival status,patients were divided into the good prognosis group (65 cases) and poor prognosis group (29 cases) to compare the differences in procalcitonin and D-dimer levels between groups. Results The levels of procalcitonin of the COPD patient group was (1.47±0.32) μg/L and the D-dimer was (1228.08±120.45) μg/L,which were significantly higher than (0.28±0.12) and (270.45±50.10) μg/L in the healthy control group,and the difference was statistically significant. Further analysis revealed that the levels of procalcitonin and D-dimer in the poor prognosis group were higher than those in the good prognosis group. However,differences in gender,age,BMI,and other factors between the two groups were not significant. Multivariate Logistic regression analysis indicated that procalcitonin[OR=1.484;95％CI=(1.093,2.015)]and D-dimer[OR=2.018;95％CI=(1.110,3.669)]were significant independent influencing factors for poor prognosis. This suggested that even after controlling for other variables,these two indicators still had a significant impact on prognosis. Conclusion This study indicates that elevated levels of serum procalcitonin and D-dimer are closely related to poor prognosis in patients with acute exacerbation of COPD complicated by type Ⅱ respiratory failure. Therefore,clinicians should pay attention to the levels of these two biomarkers to better predict the course and outcomes of patients.
万方数据
维普
